Cargando…
Dual targeting of RANKL and PD‐1 with a bispecific antibody improves anti‐tumor immunity
OBJECTIVES: The addition of RANKL/RANK blockade to immune checkpoint inhibitors (ICIs) such as anti‐PD‐1/PD‐L1 and anti‐CTLA4 antibodies is associated with increased anti‐tumor immunity in mice. Recent retrospective clinical studies in patients with advanced melanoma and lung cancer suggest the addi...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763724/ https://www.ncbi.nlm.nih.gov/pubmed/31572609 http://dx.doi.org/10.1002/cti2.1081 |